MODDERN

Personalized medicine proponents have revived legislation seeking to improve the reimbursement system for diagnostics and to incentivize the development of companion tests that pick out best responders to drugs.

Originally published Oct. 1.
A new bill strongly supported within the diagnostics industry could put pressure on the Centers for Medicare & Medicaid Services to alter its procedures for setting reimbursement rates for molecular diagnostics.

Representative Leonard Lance (R-NJ) recently introduced a bill that includes proposals for enhancing the reimbursement system for diagnostic tests, as well as incentives for pharmaceutical firms to revive unapproved drugs in their pipelines as treatments for unmet medical need.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.